HWKNMEDIUM SIGNALFINANCIAL10-K

HWKN's operating cash flow declined 30% to $111.1M while the company expanded operations and increased debt levels, suggesting potential cash generation pressures despite revenue growth.

The significant drop in operating cash flow combined with declining cash reserves and rising liabilities indicates potential working capital management challenges or increased investment needs. While gross profit and operating income grew solidly, the disconnect between earnings growth and cash generation warrants monitoring for sustainability of the business expansion.

Comparing 2025-05-14 vs 2024-05-15View on EDGAR →
FINANCIAL ANALYSIS

HWKN showed mixed financial performance with revenue-driven growth evidenced by 16.5% gross profit increase and 14.6% operating income growth, alongside asset expansion of 17%. However, the company experienced concerning cash flow deterioration with operating cash flow dropping 30% and cash reserves declining 29%, while total liabilities surged 23% despite debt reduction of 16%. This pattern suggests the company is investing heavily in growth but struggling with working capital efficiency, as evidenced by the 15% increase in accounts receivable outpacing revenue growth indicators.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-30.3%
$159.5M→$111.1M

Operating cash flow fell 30.3% — earnings quality concerns; investigate working capital changes and non-cash items.

Cash & Equivalents
Balance Sheet
-28.7%
$7.2M→$5.1M

Cash decreased 28.7% — monitor burn rate and upcoming capital needs.

Total Liabilities
Balance Sheet
+22.9%
$251.9M→$309.6M

Liabilities increased 22.9% — monitor debt-to-equity ratio and interest coverage.

SG&A Expense
P&L
+18.7%
$89.6M→$106.4M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Total Assets
Balance Sheet
+17%
$657.9M→$769.9M

Asset base grew 17% — expansion through organic growth, acquisitions, or capital deployment.

Gross Profit
P&L
+16.5%
$193.6M→$225.5M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Total Debt
Balance Sheet
-15.8%
$101.0M→$85.0M

Debt reduced 15.8% — deleveraging strengthens balance sheet and reduces financial risk.

Accounts Receivable
Balance Sheet
+15.1%
$114.5M→$131.8M

Receivables grew 15.1% — monitor days sales outstanding for collection efficiency.

Operating Income
P&L
+14.6%
$104.0M→$119.2M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Current Assets
Balance Sheet
+13.7%
$202.8M→$230.7M

Current assets grew 13.7% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2025-05-14
PRIOR — 2024-05-15
ADDED
As of May 9, 2025, the Registrant had 20,800,012 shares of common shares outstanding.
Except as required by law, we disclaim any intent or obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
References to "fiscal 2026" means our fiscal year ending March 29, 2026, fiscal 2025 means our fiscal year ended March 30, 2025, fiscal 2024 means our fiscal year ended March 31, 2024, and fiscal 2023 means our fiscal year ended April 2, 2023.
Annual Report on Form 10-K For the Fiscal Year Ended March 30, 2025 Page PART I ITEM 1.
BUSINESS We are a leading water treatment and specialty ingredients company that formulates, manufactures, distributes, and blends products for our Water Treatment, Industrial and Health and Nutrition customers.
The Water Treatment group operates out of 50 warehouses, primarily located in the eastern two-thirds of the United States, supplying products and services to customers in nearly all 50 states.
This group s principal products are acids, alkalis and food and pharmaceutical-grade salts and ingredients.
Agricultural sales within this group tend to be seasonal, with higher sales during the typical planting season of March through June given our concentration in the upper Midwest.
In addition, we operate a fleet of approximately 400 commercial vehicles, primarily in our Water Treatment Group, which are highly regulated, including by the U.S.
As of March 30, 2025, we had 1,035 employees across the United States, of which 1,031 were full-time employees.
REMOVED
As of May 10, 2024, the Registrant had 20,912,338 shares of common shares outstanding.
We are not obligated to update these statements or publicly release the result of any revisions to them to reflect events or circumstances after the date of this Annual Report on Form 10-K or to reflect the occurrence of unanticipated events.
References to "fiscal 2025" means our fiscal year ending March 30, 2025, fiscal 2024 means our fiscal year ended March 31, 2024, fiscal 2023 means our fiscal year ended April 2, 2023, and fiscal 2022 means our fiscal year ended April 3, 2022.
Annual Report on Form 10-K For the Fiscal Year Ended March 31, 2024 Page PART I ITEM 1.
BUSINESS We are a leading specialty chemical and ingredients company that formulates, distributes, blends and manufactures products for our Industrial, Water Treatment and Health and Nutrition customers.
This group s principal products are acids, alkalis and food-grade and pharmaceutical salts and ingredients.
Agricultural sales within this group tend to be seasonal, with higher sales during the typical planting season of March through June given the regions of the country we serve.
The Water Treatment group operates out of 47 warehouses supplying products and services to customers in 46 states.
In addition, we operate a fleet of more than 350 commercial vehicles, primarily in our Water Treatment Group, which are highly regulated, including by the U.S.
As of March 31, 2024, we had 934 employees across the United States, of which 928 were full-time employees.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →